Drug intelligence / Profile preview

CTS-1027 + pegylated interferon + ribavirin

Development stage: Unknown
Lead developer: Conatus Pharmaceuticals
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral, Subcutaneous, Intravenous

Overview

A combination therapy composed of **CTS-1027**, a selective small-molecule inhibitor of matrix metalloproteinases (MMPs), **pegylated interferon** (a modified form of interferon alfa with improved pharmacokinetics), and **ribavirin**, a nucleoside analogue antiviral. CTS-1027 inhibits MMP activity, thereby attenuating liver injury and fibrosis in preclinical models, and was investigated for anti-fibrogenic and hepato-protective effects[1][4][7][9]. Pegylated interferon exerts antiviral, immunomodulatory, and antiproliferative actions, while ribavirin enhances the sustained virological response against hepatitis C virus (HCV)[2][3][5][10]. The combination has been studied for potential improvement in chronic hepatitis C treatment outcomes, particularly targeting viral eradication and reduction of liver fibrosis[9].

Brand names: PegasysCopegus
Other names: pegylated interferon-Conatus Pharmaceuticals Inc.-hepatitis Cpegylated interferonribavirinpeginterferon alfa-2a

Targets

IFNAR (Immune system modulation via type I interferon receptor)MMP8 (Neutrophil collagenase)MMP12 (Macrophage Metalloelastase)MMP2 (Matrix metalloproteinase-2)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)MMP3 (Matrix metalloproteinase-3)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)HCV RNA (Hepatitis C virus RNA)MMP13 (Matrix metalloproteinase-13)

Beyond the preview

Go deeper on CTS-1027 + pegylated interferon + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTS-1027 + pegylated interferon + ribavirin.

Explore the full profile